These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32228183)

  • 1. Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan.
    Ishida Y; Murayama H; Shinfuku Y; Taniguchi T; Sasajima T; Oyama N
    Expert Opin Drug Saf; 2020 May; 19(5):625-631. PubMed ID: 32228183
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
    Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
    Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Matsukawa M; Yamada Y
    Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of patient background with macro- and microvascular complications: a 2-year post-marketing surveillance of vildagliptin in nearly 20,000 Japanese diabetic patients.
    Murayama H; Toda M; Tsumiyama I; Shinfuku Y; Taniguchi T; Tanaka Y; Oyama N
    Expert Opin Pharmacother; 2019 Jun; 20(8):1037-1047. PubMed ID: 30831038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study.
    Shelbaya S; Rakha S
    Curr Med Res Opin; 2017 May; 33(5):797-801. PubMed ID: 28303721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
    Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
    Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study.
    Yoshikawa K; Tsuchiya A; Kido T; Ota T; Ikeda K; Iwakura M; Maeda Y; Maekawa S
    Adv Ther; 2020 May; 37(5):2442-2459. PubMed ID: 32306246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
    Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
    Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y; Usami M; Inoue T
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
    Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
    Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
    McInnes G; Evans M; Del Prato S; Stumvoll M; Schweizer A; Lukashevich V; Shao Q; Kothny W
    Diabetes Obes Metab; 2015 Nov; 17(11):1085-92. PubMed ID: 26250051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.
    Goda M; Yamakura T; Sasaki K; Tajima T; Ueno M
    Curr Med Res Opin; 2018 Feb; 34(2):319-327. PubMed ID: 29025285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
    Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
    Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE; Bhosekar V; Kawamori R
    Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients.
    Dobrecky-Mery I; Sommer A
    Coron Artery Dis; 2021 Jan; 32(1):4-9. PubMed ID: 32310854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Haneda M; Ito H; Ueno M; Matsukawa M; Yamakura T; Sasaki K; Kimura M; Iijima H
    Expert Opin Pharmacother; 2018 Feb; 19(2):83-91. PubMed ID: 29268035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
    Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
    Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.